5 completed, 2 terminated, 1 recruiting, 1 unknown. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Terminated 2, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Toxicity: new trials by email Literature Review of Toxicity trials Research Report on Toxicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study Short Chain Fatty Acid, Tapioca Flour - Toxicity, Radiation Toxicity | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 122 | 2023-12-15 | 2026-10-05 |
| A Study of GFH312 in Healthy Subjects GFH312, Placebo - Toxicity, Healthy | Phase 1 | Completed | GenFleet Therapeutics (Australia) Pty Ltd. | 76 | 2021-04-27 | 2023-05-15 |
| Safety Assessment of P2Et Extract in Healthy Voluntary Subjects in Colombia P2Et extract - Toxicity, Safety Issues | Phase 1 | Completed | Hospital Universitario San Ignacio | 7 | 2019-04-30 | 2024-03-13 |
| Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients N-Methanocarbathymidine, Placebo Capsule - Toxicity | Phase 1 | Unknown | N&N Pharmaceuticals Inc. | 28 | 2016-04-01 | 2016-09-22 |
| The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) Nab-paclitaxel - Esophageal Cancer, Toxicity | Phase 1 / Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 154 | 2014-10-01 | 2017-05-31 |
| External Beam Radiotherapy for Muscle Invasive Bladder Cancer external beam radiotherapy (EBRT) - Toxicity | Phase 1 | Completed | University Hospital, Ghent | 77 | 2014-08-01 | 2022-12-27 |
| Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion transdermal DMPS - Toxicity | Phase 1 | Completed | Banner Health | 9 | 2010-04-01 | 2011-06-22 |
| Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer bevacizumab - Toxicity | Phase 1 | Terminated | Amsterdam UMC, location VUmc | 6 | 2007-10-01 | 2011-04-05 |
| MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel - Esophageal, Toxicity | Phase 1 / Phase 2 | Terminated | Joel Greenberger | 18 | 2005-11-11 | 2021-11-12 |
Radiation Injuries (2) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
Neoplasms (3) · Neoplasms by Site (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Wounds and Injuries (2) · Esophageal Diseases (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1)
(north)-methanocarbathymidine (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Butyric Acid (1) · Carboplatin (1) · Fatty Acids, Volatile (1) · Paclitaxel (1) · Radiotherapy (1) · sodium propionate (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Amsterdam UMC, location VUmc (1) · Banner Health (1) · GenFleet Therapeutics (Australia) Pty Ltd. (1) · Hospital Universitario San Ignacio (1) · Joel Greenberger (1) · N&N Pharmaceuticals Inc. (1) · UNC Lineberger Comprehensive Cancer Center (1) · University Hospital, Ghent (1)
United States (4) · Netherlands (2) · Australia (1) · Belgium (1) · Colombia (1)
Anne-Michelle Ruha, M.D. (1) · Aquilur Rahman, PhD (1) · Egbert F Smit, MD, PhD (1) · Hanneke WM van Laarhoven, Prof.Dr. (1) · Joel Greenberger, MD (1) · Lilian Torregrosa Almonacid, MD (1) · Shivani Sud, MD (1) · Suresh Senan, MD, PhD (1)